ANAPTYSBIO, INC

AnaptysBio, Inc. announced the post-trial briefing schedule for its consolidated litigation against Tesaro, Inc. and GlaxoSmithKline. The trial concluded on July 17, 2026, and a Joint Stipulation and Proposed Order for the schedule was granted by the Delaware Court of Chancery on July 28, 2026. The schedule outlines deadlines for opening, answering, and reply briefs, with post-trial arguments set for October 20, 2026.

AnaptysBio, Inc. has scheduled its 2026 Annual Meeting of Stockholders for August 11, 2026. Stockholders of record as of June 22, 2026, will vote on several key proposals, including the election of two Class III directors, the ratification of KPMG LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Additionally, stockholders will consider an amendment to the company's 2017 Equity Incentive Plan. Proxy materials were made available to stockholders on or about June 29, 2026.

AnaptysBio, Inc. has entered into a Sublease Agreement with First Tracks Biotherapeutics, Inc., effective June 15, 2026. Under the agreement, AnaptysBio will sublease approximately 45,057 square feet of its San Diego premises for an initial term of twelve months. First Tracks will pay monthly rent equivalent to AnaptysBio's obligations under its Master Lease and has an option to extend the sublease.

AnaptysBio, Inc. has filed Form 8937 with the IRS, which will also be available on its website. This form provides details regarding the dividend received by stockholders from the separation and spin-off of First Tracks Biotherapeutics, Inc. The filing includes guidance on the tax treatment of the dividend and how to determine changes in tax basis, advising stockholders to consult their own tax advisors.

AnaptysBio, Inc. completed the separation of its business into two independent, publicly traded companies on April 20, 2026. The original company will focus on managing financial collaborations for Jemperli and imsidolimab royalties, while the spun-out entity, First Tracks Biotherapeutics, will develop autoimmune and inflammatory disease therapeutics. For the first quarter of 2026, AnaptysBio reported a net loss of $(52.9) million, an increase from $(39.3) million in the prior year, with collaboration revenue decreasing to $25.6 million.

AnaptysBio, Inc. completed the spin-off of First Tracks Biotherapeutics, Inc. in late April 2026, now exclusively managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. The company reported a Q1 2026 net loss of $52.9 million, or $1.84 per share, on collaboration revenue of $25.6 million. AnaptysBio also announced the appointment of Chris Murphy as CFO and Susannah Gray and Owen Hughes to its Board of Directors, alongside a $100.0 million stock repurchase plan.

AnaptysBio, Inc. announced the appointment of Christopher M. Murphy as Chief Financial Officer, effective May 11, 2026. Mr. Murphy will receive a monthly consulting fee of $42,916.66, an annual target cash bonus of up to 40% of his fees, and an equity grant worth $1,750,000 in restricted stock units. Additionally, Owen Hughes was appointed as a Class I director, effective May 11, 2026, and will receive an initial grant of 11,250 restricted stock units.

AnaptysBio, Inc. announced that Daniel Faga, its President and Chief Executive Officer, is scheduled to participate in a fireside chat. The event will take place at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026, starting at 1:30pm ET. The company focuses on managing financial collaborations for Jemperli with GSK and imsidolimab with Vanda, aiming to protect and return royalty value to shareholders.

ANAPTYSBIO, INC. completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., as a pro rata dividend to stockholders on April 20, 2026. In connection with this divestment, Eric Loumeau, Paul Lizzul, M.D., Ph.D., and Dennis Mulroy separated from the company. The board of directors was also reclassified due to the departure of four members, ensuring equal apportionment across its three classes. This 10-K/A filing provides detailed corporate governance, executive compensation for 2025, and a summary of 2025 corporate milestones.

ANAPTYSBIO, INC filed a 10-K/A to amend its annual report, including corporate governance and executive compensation details. The company completed the spin-off of its subsidiary, First Tracks Biotherapeutics, Inc., on April 20, 2026, distributing all outstanding shares as a pro rata dividend. In connection with this spin-off, three executives, including two named executive officers for 2025 (Paul Lizzul and Dennis Mulroy), separated from the company. Additionally, the Board of Directors was reclassified on April 27, 2026, to ensure equal apportionment among its three classes following the departure of four members. The filing also detailed 2025 executive compensation and non-employee director compensation.